Long-term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials
Fred Poordad, Rui Sarmento E. Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Douglas Dieterich, Rui Tato Marinho, Armando Carvalho, Asma Siddique, Yiran Bonnie Hu, Mariem Charafeddine, Mark Bondin, Nader Khan, Daniel E. Cohen, Franco Felizarta
Research output: Contribution to journal › Article › peer-review
12Scopus
citations
Fingerprint
Dive into the research topics of 'Long-term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials'. Together they form a unique fingerprint.